TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Exercise-induced Changes in DNA-methylation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* 70-75 years old~* Signed written informed consent~Exclusion Criteria:~* Incompatible with exercise~* Known cardiac disease~* Active cancer~* Significant pulmonary disease~* Uncontrolled hypertension~* Use of blood thinning medicine (except Albyl-E)~* Drug abuse~* Alcohol abuse~* Finishing less than 80% of the exercise sessions (this complies to the training groups)

- Gender: MALE
- Minimum Age: 70 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- High-intensity interval training (Type: EXPERIMENTAL): The High-intensity interval training group was instructed to complete exercise sessions of 4x4-minutes intervals at 85-95% of maximal heart rate, 3 times a week for 8 weeks. This type of exercise include 10 minutes warm-up, followed by four intervals of four minutes high-intensity (85-95% of HRmax), with three minutes active breaks (70% of HRmax) between each interval, and ending with seven minutes cool-down. An exercise session last for 42 minutes, where the participants should breathe heavily and feel exhausted four times.
- Moderate training (Type: ACTIVE_COMPARATOR): The moderate training group was instructed to complete exercise sessions of 50 minutes at 70% of maximal heart rate, 3 times a week for 8 weeks.
- Control (Type: NO_INTERVENTION): The control group followed the baseline and follow-up tests, and was asked to live normally and not change their dietary pattern or exercise habits during their participation in this project. Based on the well-known beneficial effects of exercise on general health, it was regarded unethical to demand the control group to desist from any types of physical activity during the project period. They got no further follow-up on exercise.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Gastrointestinal Quality of Life Study in Lung Transplant Recipients Converted From Mycophenolate Mofetil to Myfortic

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability and willingness to provide written informed consent and adhere to study regimen~* Recipients who are 18-70 years of age~* Patients who have undergone either single or double lung transplant are discharged on the standard MMF (no generic MMF will be used) therapy and complain of GI symptoms, thought to be related to their immunosuppressive regimen~Exclusion Criteria:~* Patients who have GI complaints thought to be due to factors other than immunosuppressive regimen~* Patients receiving steroid treatment for acute rejection~* Women of childbearing potential who do not agree to use at least two acceptable forms of contraception prior to starting study drug, while taking study drug, and for 6 weeks after stopping study drug~* Women who have a positive serum or urine pregnancy test at visit 1 and/or continuing through the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Patients taking Myfortic (Type: OTHER): Lung transplant patients converted from MMF to Myfortic as part of standard of care treatment will have GI and Quality of Life assessments done at the time of conversion to Myfortic and at 60 days, 90 days and 180 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Angioid Streaks~* Choroidal neovascularization associated~* Untreated patients or patients treated once with PDT~Exclusion Criteria:~* Ocular surgery excepting uncomplicated phacoemulsification~* Glaucoma or any other ocular pathology

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cemented vs. Cementless TKA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Evaluation for TKA at OrthoCarolina~2. Evaluated and scheduled for TKA by Drs. Keith Fehring, Bo Mason, William Griffin, Thomas Fehring, or Jesse Otero~3. Determined by the above surgeon to be a candidate for the Attune Posterior Stabilized knee system, with the patella to be resurfaced during surgery~4. \>18 years of age at enrollment~Exclusion Criteria:~1. Previous surgery with hardware on the joint of interest~2. \>= 65 years old at the time of TKA surgery~3. Previous diagnosis of inflammatory disease (RA, inflammatory arthropathy, any autoimmune disease)~4. BMI \<= 40~5. Physician discretion due to not being able to follow standard-of-care (SOC) TKA follow up protocol~6. History of contralateral TKA~7. Current Tobacco Use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment/Intervention (Type: ACTIVE_COMPARATOR): Total Knee Arthroplasty (TKA) with cementless knees
- Control (Type: ACTIVE_COMPARATOR): Total Knee Arthroplasty (TKA) with cemented knees

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Varying Portion Size and Palatability on Food Intake of Preschool Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Children who are enrolled in a scheduled classroom of the designated childcare centers~Exclusion Criteria:~* Children who are allergic to any of the foods served~* Children whose diets exclude any of the foods served~* Children who will not be present at the childcare center for all of the scheduled study days

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Smaller Portion Size and Standard Appeal (non-divided plate) (Type: EXPERIMENTAL): Food with Smaller Portion Size and Standard Appeal on a non-divided plate
- Smaller Portion Size and Enhanced Appeal (divided plate) (Type: EXPERIMENTAL): Food with Smaller Portion Size and Enhanced Appeal on a divided plate
- Larger Portion Size and Standard Appeal (non-divided plate) (Type: EXPERIMENTAL): Food with Larger Portion Size and Standard Appeal on a non-divided plate
- Larger Portion Size and Enhanced Appeal (divided plate) (Type: EXPERIMENTAL): Food with Larger Portion Size and Enhanced Appeal on a divided plate
- Smaller Portion Size and Standard Appeal (divided plate) (Type: EXPERIMENTAL): Food with Smaller Portion Size and Standard Appeal on a divided plate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically confirmed malignant mixed mesodermal (MMMT) confined to the pelvis (Stage IB, IC, IIA, IIB, IIIA).~* Patients who have undergone a total abdominal hysterectomy, vaginal hysterectomy or laparoscopic assisted vaginal hysterectomy and a bilateral salpino-oophorectomy (with minimal surgical staging, including omental biopsy and lymph node sampling) within 8 weeks of study entry.~* No known metastatic extrauterine metastases, no known gross residual disease or distant metastases.~* Women of any racial or ethnic group are eligible.~* Zubrod performance status of \</= 2.~* Adequate bone marrow, renal and hepatic function: Hgb \> 10 gm/dl, ANC \>1.5/mm3, Platelets \> 100,000/mcl, Creatinine \< 1.5 mg/%, Bilirubin \< 2.5 mg/dl, SGPT \< 2\* ULN, BUN \< 1.5\* ULN.~* No prior chemotherapy or radiation therapy for this diagnosis.~* Estimated life expectancy of 12 weeks or greater.~* Must sign an institutionally approved informed consent.~Exclusion Criteria:~* Previously treated malignant mixed mesodermal (MMMT) with either chemotherapy or radiotherapy (XRT)/~* Patients with gross residual disease, suspected extrapelvic or extrauterine disease or distant metastatic disease (Stage IIIB, IIIC or IV).~* History of other malignancy, with the exception of non-melanomatous skin cancer, unless in complete remission and off all therapy for that disease for a minimum of 5 years.~* Patients with a Zubrod performance status of 3 or greater.~* Patients with an active systemic infection.~* Patients with a serious intercurrent medical illness.~* Patients with a recent (within 6 months) history of cardiac dysrhythmia, congestive heart failure, unstable angina or myocardial infarction.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiation + Chemotherapy (Type: EXPERIMENTAL): Radiation with weekly Cisplatin 40 mg/m\^2 intravenously (IV) Followed by Carboplatin (AUC 5 IV)/Paclitaxel (135 mg/m\^2 IV) Chemotherapy every 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subjects are voluntary and sign the informed consent form;~* ECOG score 0 to 2;~* The expected survival time ≥3 months;~* Patients with cutaneous T-cell lymphoma confirmed by histopathology, with measurable lesions, with or without systemic lymph node involvement; clinical stage IB-IVA;~* The patients previously receive at least once of systemic therapy (including systemic electron beam irradiation or chemotherapy, stem cell transplantation) and do not achieve remission (including remission period shorter than 30 days after the treatment;~* An interval of at least four weeks after the target tumor was treated with chemotherapy, radiotherapy, biological therapy, stem cell transplantation or other study drugs;~* Subjects at childbearing age agree to take effective contraceptive measures during the study; blood pregnancy test result is negative (except infertility due to menopause or operation);~* Laboratory tests (blood routine, liver and kidney function) meet the following requirements:~  1. ANC≥ 1.5×109/L; b) PLT ≥ 75×109/L; c) Hb ≥ 9 g/dL; d) Cr) ≤ 1.5x ULN ; e) TBIL ≤ 1.5x ULN; f) AST or ALT ≤2.5 x ULN.~Exclusion Criteria:~* Pregnant or lactating women;~* An allergic history to anthracyclines or liposome drugs;~* Disease progression or recurrence after anthracycline treatment within six months before the enrollment;~* Patients who once used mitoxantrone injection;~* Patients who have used doxorubicin (or pirarubicin) with the total cumulative dose\> 360mg/m2, or epirubicin with the total cumulative dose \> 600mg/m2;~* Left ventricular ejection fraction is \< 50% or \< the lower limit of normal; clinically significant QT interval prolongation (\>450ms in male, \>470ms in female); a past history of cardiac disease caused by anthracyclines; a history of severe heart disease;~* Concomitant treatment as other anticancer drugs are needed;~* With internal organ involvement (including bone marrow, central nervous system;~* Clinically active infection that can significantly affect the clinical trial;~* Within 6 weeks after organ transplantation or major organ surgery;~* Those who are inappropriate to be enrolled as evaluated by the researchers.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Mitoxantrone HCL Liposome Injection (Type: EXPERIMENTAL): Each treatment cycle lasts for 28 days with 20mg/m2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Water Drinking Test During Intraocular Pressure Fluctuation (IOP) Monitoring

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteer without previous ocular medical history~* 18 years or more at inclusion~* Maximal weight: 100kg~* BMI lower or equal to 30 kg/m2~* Subjects having provided informed consent~Exclusion Criteria:~* Silicone allergy~* Cardiovascular disease~* Diabetes~* Narrow or closed iridocorneal angle

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Morphine in Moderate Obstructive Sleep Apnoea

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years~2. Patients with diagnosis of moderate or severeOSA at screening, diagnosed by nocturnal oximetry, rPSG or PSG (defined as AHI or ODI of 15-50 events/hour) established on Continuous Positive Airway Pressure (CPAP)~3. Patients established on CPAP with confirmed moderate OSA (AHI 15-29 events/hr) 6 nights after withdrawal of CPAP (confirmed at baseline rPSG)~4. Patients diagnosed with moderate OSA by rPSG or PSG, naïve to CPAP treatment~Exclusion Criteria:~* Inability to give informed consent or comply with the protocol~* Current, clinically significant acute respiratory tract infection (at screening and at study visit)~* Chronic respiratory disease (other than OSA), symptomatic ischemic heart disease~* Pregnancy or suspected pregnancy/breast feeding~* Current or recent (within last week of entering the trial and for the duration fo the trial) use of gabapentin, pregabalin, melatonin, mirtazapine, benzodiazepines, barbiturates, sodium oxybate, ramelteon, Z-drugs and opiates/opioids~* Monoamine oxidase inhibitors (MAOIs), linezolid taken within two weeks of participation in the trial~* A known allergy to the investigational medicinal product (IMP) or non investigational medicinal product(s) (NIMP)(s)~* Patients with an inadequate command of English and such that an interpreter would be required overnight~* Change in weight of greater than 5% since the baseline rPSG~* Vital signs recordings (oxygen saturations, blood pressure, pulse rate) that in the clinician's opinion deem the patient unsafe to participate in the trial~* Clinician deems the patient unsafe to participate in the trial (e.g. severely sleepy patients who cannot withdraw from CPAP)~* CPAP intolerant/poor responder~* History of drug abuse (oral and intravenous) including: alcohol, substituted amphetamines, barbiturates, benzodiazepines, cocaine, methaqualone, cannabis and opioids~* A drop of oxygen saturations below 85% continuously for longer than five minutes during the baseline rPSG~* Professional driver

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Morphine sulphate (Type: EXPERIMENTAL): Participants will be given a first dose of morphine sulphate (intravenously) before bedtime and a second dose four hours later. In both instances 4 mg of intravenous ondansetron will be administered after the morphine sulphate dose to prevent sickness

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Alemtuzumab + Rituximab Consolidation in CLL

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with CLL, CLL/prolymphocytic leukemia (PLL), or Small Lymphocytic Lymphoma (SLL) who have achieved an National Cancer Institute-Working Group (NCI-WG) nodular partial (nPR) or complete response (CR) with documentation of residual disease by MRD flow cytometry following chemotherapy or chemoimmunotherapy.~* Patients with CLL, CLL/PLL, or SLL who have achieved an NCI-WG partial response (PR) following prior chemotherapy or chemoimmunotherapy.~* Age \>/=18 years.~* ECOG performance status \</=2.~* Serum creatinine \</= 2 mg/dL; serum total bilirubin \</= 2 mg/dL; serum AST or ALT \<4 x ULN.~* Signed informed consent.~* Male and female patients who are fertile agree to use an effective barrier method of birth control (ie, latex condom, diaphragm, cervical cap, etc.) to avoid pregnancy. Female patients of childbearing potential (non-childbearing is defined as \>/= 1 year post-menopausal or surgically sterilized) need a negative serum or urine pregnancy test within 14 days of study enrollment.~Exclusion Criteria:~* Past history of anaphylaxis following exposure to rat or mouse derived complementarity determining region (CDR)-grafted humanized monoclonal antibodies.~* Hormonal therapy within 2 weeks prior to study start. Hormonal replacement therapy is permitted.~* Active Hepatitis B (at least one of the following markers positive: HBsAg, HBeAg, IgM anti-HBc, HBV DNA).~* Previous treatment with alemtuzumab plus rituximab in combination.~* Pregnant or nursing women.~* History of HIV infection.~* Active uncontrolled infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).~* Less than 6 months from the completion of prior chemotherapy or chemoimmunotherapy. Completion of prior chemoimmunotherapy is defined as the last day of therapy of the respective treatment regimen.~* Symptomatic CNS disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: EXPERIMENTAL): Group 1: 375 mg/m\^2 IV Rituximab Alone
- Alemtuzumab (Type: EXPERIMENTAL): Group 2: 30 mg SQ Alemtuzumab Alone
- Rituximab + Alemtuzumab (Type: EXPERIMENTAL): Group 3: 375 mg/m\^2 Rituximab + 30 mg SQ Alemtuzumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical signs and symptoms of ADON in one eye (loss of vision, pain on movement, impairment of color vision)~* First episode of ADON~* Able to undergo treatment with IV steroids~Exclusion Criteria:~* History of any unexplained eye or neurological symptoms lasting longer than 48 hours~* Optic neuritis in both eyes~* Concomitant condition in either eye, other than optic neuritis~* History of heart condition/disease~* Patients with uncontrolled diabetes mellitus~* Patients with liver conditions/disease~* Inability to undergo MRI~* Pregnant or nursing women~* Women of childbearing potential who are not using highly effective method of birth control~  * Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Fingolimod 0.5mg/daily (Type: EXPERIMENTAL): Oral capsule dose was given once daily for 48 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Patients received oral dose of placebo from Weeks 0-18, followed by oral dose of fingolimod 0.5/mg capsule from Weeks 18-48

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility